Cargando…

Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial

INTRODUCTION: Acute exacerbation (AE) is a major cause of disease progression and death in patients with chronic obstructive pulmonary disease (COPD), accounting for majority of medical expenditures. Correct inhalation therapy is effective in preventing AE attacks. However, inappropriate usage of dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Jianlan, Zhang, Wei, Cao, Hui-fang, Du, Chun-ling, Ma, Jia-yun, Zuo, Yi-hui, Zhang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228517/
https://www.ncbi.nlm.nih.gov/pubmed/32385061
http://dx.doi.org/10.1136/bmjopen-2019-034804
_version_ 1783534602547101696
author Hua, Jianlan
Zhang, Wei
Cao, Hui-fang
Du, Chun-ling
Ma, Jia-yun
Zuo, Yi-hui
Zhang, Jing
author_facet Hua, Jianlan
Zhang, Wei
Cao, Hui-fang
Du, Chun-ling
Ma, Jia-yun
Zuo, Yi-hui
Zhang, Jing
author_sort Hua, Jianlan
collection PubMed
description INTRODUCTION: Acute exacerbation (AE) is a major cause of disease progression and death in patients with chronic obstructive pulmonary disease (COPD), accounting for majority of medical expenditures. Correct inhalation therapy is effective in preventing AE attacks. However, inappropriate usage of dry powder inhaler, partially due to the unrecovered peak inhalation flow rate (PIFR) after acute exacerbation of COPD (AECOPD), results in increased risk of early treatment failure. Therefore, we designed a multicentre, randomised clinical trial to determine whether PIFR-based optimised inhalation therapy and training on inhaler usage at discharge could effectively reduce early treatment failure events. METHODS AND ANALYSIS: A total of 416 hospitalised patients just recovering from AECOPD will be recruited and equally randomised into the PIFR group and the control group at a 1:1 ratio. The PIFR group will receive additive support before discharge, including choice of PIFR-guided inhaler and education on its usage. PIFR is measured by InCheck DIAL. In comparison, the control group will receive inhalers based on judgement of the respiratory physician. The primary outcome of the study is 30-day treatment failure rate. Other endpoints include PIFR, error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms and quality of life of patients, and COPD-related treatment costs. ETHICS AND DISSEMINATION: The trial has been approved by the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142). Participants will be screened and enrolled from hospitalised patients with AECOPD by clinicians, with no public advertisement for recruitment. After the trial has completed, the results will be reported to the public through conference presentations and peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04000958.
format Online
Article
Text
id pubmed-7228517
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-72285172020-05-18 Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial Hua, Jianlan Zhang, Wei Cao, Hui-fang Du, Chun-ling Ma, Jia-yun Zuo, Yi-hui Zhang, Jing BMJ Open Respiratory Medicine INTRODUCTION: Acute exacerbation (AE) is a major cause of disease progression and death in patients with chronic obstructive pulmonary disease (COPD), accounting for majority of medical expenditures. Correct inhalation therapy is effective in preventing AE attacks. However, inappropriate usage of dry powder inhaler, partially due to the unrecovered peak inhalation flow rate (PIFR) after acute exacerbation of COPD (AECOPD), results in increased risk of early treatment failure. Therefore, we designed a multicentre, randomised clinical trial to determine whether PIFR-based optimised inhalation therapy and training on inhaler usage at discharge could effectively reduce early treatment failure events. METHODS AND ANALYSIS: A total of 416 hospitalised patients just recovering from AECOPD will be recruited and equally randomised into the PIFR group and the control group at a 1:1 ratio. The PIFR group will receive additive support before discharge, including choice of PIFR-guided inhaler and education on its usage. PIFR is measured by InCheck DIAL. In comparison, the control group will receive inhalers based on judgement of the respiratory physician. The primary outcome of the study is 30-day treatment failure rate. Other endpoints include PIFR, error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms and quality of life of patients, and COPD-related treatment costs. ETHICS AND DISSEMINATION: The trial has been approved by the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142). Participants will be screened and enrolled from hospitalised patients with AECOPD by clinicians, with no public advertisement for recruitment. After the trial has completed, the results will be reported to the public through conference presentations and peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04000958. BMJ Publishing Group 2020-05-07 /pmc/articles/PMC7228517/ /pubmed/32385061 http://dx.doi.org/10.1136/bmjopen-2019-034804 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Respiratory Medicine
Hua, Jianlan
Zhang, Wei
Cao, Hui-fang
Du, Chun-ling
Ma, Jia-yun
Zuo, Yi-hui
Zhang, Jing
Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial
title Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial
title_full Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial
title_fullStr Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial
title_full_unstemmed Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial
title_short Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial
title_sort effect of pifr-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial
topic Respiratory Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228517/
https://www.ncbi.nlm.nih.gov/pubmed/32385061
http://dx.doi.org/10.1136/bmjopen-2019-034804
work_keys_str_mv AT huajianlan effectofpifrbasedoptimisedinhalationtherapyinpatientsrecoveringfromacuteexacerbationofchronicobstructivepulmonarydiseaseprotocolofaprospectivemulticentresuperiorityrandomisedcontrolledtrial
AT zhangwei effectofpifrbasedoptimisedinhalationtherapyinpatientsrecoveringfromacuteexacerbationofchronicobstructivepulmonarydiseaseprotocolofaprospectivemulticentresuperiorityrandomisedcontrolledtrial
AT caohuifang effectofpifrbasedoptimisedinhalationtherapyinpatientsrecoveringfromacuteexacerbationofchronicobstructivepulmonarydiseaseprotocolofaprospectivemulticentresuperiorityrandomisedcontrolledtrial
AT duchunling effectofpifrbasedoptimisedinhalationtherapyinpatientsrecoveringfromacuteexacerbationofchronicobstructivepulmonarydiseaseprotocolofaprospectivemulticentresuperiorityrandomisedcontrolledtrial
AT majiayun effectofpifrbasedoptimisedinhalationtherapyinpatientsrecoveringfromacuteexacerbationofchronicobstructivepulmonarydiseaseprotocolofaprospectivemulticentresuperiorityrandomisedcontrolledtrial
AT zuoyihui effectofpifrbasedoptimisedinhalationtherapyinpatientsrecoveringfromacuteexacerbationofchronicobstructivepulmonarydiseaseprotocolofaprospectivemulticentresuperiorityrandomisedcontrolledtrial
AT zhangjing effectofpifrbasedoptimisedinhalationtherapyinpatientsrecoveringfromacuteexacerbationofchronicobstructivepulmonarydiseaseprotocolofaprospectivemulticentresuperiorityrandomisedcontrolledtrial